All Activity

Missouri’s governor says the state needs to take steps to restrict the availability of intoxicating hemp-derived THC products in line with legislation that lawmakers recently sent to his desk. “At a high level, I’m very much in favor of taking these illegal drugs in the form of the candies and stuff off of the shelves for kids to be able to buy,” Gov. Mike Kehoe (R) said in an episode of This Week in Missouri Politics that aired on Sunday. While the governor said his office will “do bill review” on the specific provisions of the legislation that lawmakers passed last week, he generally agrees with its aim. “The way the legislation is drawn up is it helps us match the federal standard that’s coming down on these issues,” Kehoe said, referring to national restrictions that President Donald Trump signed into law late last year and that are set to take effect this November. “So it gives everybody, retailers, I think, until November, to get their shelves corrected and get in the right spot,” he said. “But, definitely something we need to get done.” The legislation that Kehoe is set to decide on, HB 2641 from Rep. Dave Hinman (R), would largely align the state with the forthcoming new federal rules removing products containing more than 0.4 milligrams of total THC per container from the definition of legal hemp. Under the Missouri bill, “hemp-derived cannabinoid products shall be considered marijuana and shall be subject to the legal framework” of the state’s marijuana law “under which the purchase, possession, consumption, use, delivery, manufacturing, and sale of marijuana is regulated” by the Department of Health and Senior Services. The restriction would take effect on November 12, the same date the federal policy is set to go into force. The legislation also contains provisions to protect marijuana consumers’ privacy and recognize cannabis industry workers’ right to unionize under amendments added in the Senate. The post Missouri Governor Says Restricting Hemp THC Products Is ‘Something We Need To Get Done’ As Ban Bill Heads To His Desk appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Drug Enforcement Administration (DEA) says the marijuana rescheduling appeal process “remains pending” despite President Donald Trump issuing an executive order more than three months ago directing the attorney general to enact the reform “in the most expeditious manner.” DEA and reform proponents on Monday submitted a joint status report on an interlocutory appeal that concerns allegations of agency bias and improper communications with anti-rescheduling parties during the rescheduling review process. “To date, Movants’ interlocutory appeal to the Administrator regarding their Motion to Reconsider remains pending with the Administrator,” the filing from attorneys representing DEA and cannabis reform proponents challenging the process says. “No briefing schedule has been set.” It’s up to the agency to set the briefing schedule. But nearly a year after the appeal was accepted by a former administrative law judge, DEA is again delaying the process. This is the fifth joint status report, with largely identical language, that the parties filed pursuant to the administrative court’s order. DEA Administrator Terrance Cole told senators during a confirmation hearing last year that examining the cannabis rescheduling proposal would be “one of my first priorities.” This latest filing comes months after Trump signed an executive order calling on Attorney General Pam Bondi to expeditiously finalize a rule to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). The president has since fired Bondi, replacing her on a temporary basis with DOJ official Todd Blanche as acting attorney general. During his Senate Judiciary Committee confirmation process, Blanche said in response to a written question about marijuana rescheduling that he would “give the matter careful consideration after conferring with all relevant stakeholders, including DEA personnel.” When asked about aligning federal and state marijuana laws, he said that “coordination between federal and state authorities is critically important” but that he had “not had the opportunity to study this particular issue.” Meanwhile, a leading marijuana prohibitionist group has retained the legal services of Trump’s former attorney general, Bill Barr, to sue to reverse federal marijuana rescheduling if and when the pending rule is finalized. And they’ll also be filing a petition through the administrative process to keep cannabis strictly prohibited. Moving cannabis to Schedule III wouldn’t legalize marijuana, but it would formally recognize the plant’s medical value, allow marijuana businesses to take federal tax deductions and remove certain research barriers. A recent report from the Congressional Research Service (CRS) noted that DOJ could in theory decline to enact rescheduling, or start the review process all over again, for example. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — A former DEA senior advisor recently authored a journal article arguing that current federal laws that determine how marijuana and other drugs are classified have “fundamental flaws” that have done “immense damage.” An agriculture-focused conservative nonprofit connected to a PAC linked to the president recently applauded the rescheduling order, arguing that it will “destroy” the illicit market and support seniors and military veterans who could benefit from cannabis. Separately, a coalition of Republican state attorneys general criticized Trump’s rescheduling decision, saying cannabis is “properly” classified as a Schedule I drug with no accepted medical use and a high potential for abuse. Groups of House and Senate Republican lawmakers also sent letters urging Trump not to reschedule cannabis. Trump, however, dismissed those concerns—pointing out that an overwhelming majority of Americans support the reform and that cannabis can help people who are suffering from serious health issues, including his personal friends. While the interlocutory appeal before DEA is on pause again with the latest filing, the agency did recently finalize quotas for legal production of controlled substances in 2026—further raising the amount of certain psychedelics that can be made for research purposes in the new year. Over recent years, DEA has generally ramped up production goals for marijuana and certain psychedelics as interest in their therapeutic potential has grown within the public and scientific community. Read the latest DEA filing in the rescheduling case below: The post Marijuana Rescheduling Appeal Process ‘Remains Pending’ Despite Trump’s Executive Order, DEA Says In New Filing appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A Republican congressman who President Donald Trump is campaigning to defeat in a primary election next month says states should be able to decide whether they want to legalize marijuana without federal interference. Rep. Thomas Massie (R-KY) said in a new interview with The Cincinnati Enquirer that while he doesn’t “do recreational marijuana” and personally prefers “medicinal margaritas,” he does support scaling back the war on cannabis. “I support anybody making their own decision,” the congressman said. “And the state of Kentucky should be deciding the marijuana laws for the state of Kentucky, not the federal government.” The journalist doing the interview found a curious way into the marijuana issue by first noting that Massie has referred to his off-the-grid homestead property in Kentucky as “the Shire,” a nod to the home of the hobbits in the Lord of the Rings series. She then noted that “hobbits smoke a lot of pipe-weed” before pivoting to the cannabis query. Massie, for his part, has long supported cannabis reform—telling Marijuana Moment in a 2018 interview that failing to advance marijuana legalization has been a “huge missed opportunity for Republicans.” During his time in office, the congressman has championed legislation to legalize industrial hemp and protect the Second Amendment gun rights of marijuana consumers. Massie told Fox News in 2019 that rescheduling cannabis is good politics. “The first party that does this—and I don’t understand why either party won’t do it—is going instantly gain 10 points in the general poll on which party versus the other,” he said at the time. While the congressman has supported amendments to protect state marijuana from federal interference, he did vote against a cannabis legalization bill on the House floor, saying that it “creates new marijuana crimes” for not complying with new regulations the legislation sought to create. Meanwhile, Massie has drawn Trump’s anger by pushing for release of files related to Jeffrey Epstein and for opposing key legislative initiatives such as spending bills. The president has endorsed his primary challenger, Ed Gallrein, in the May 19 election. The post GOP Congressman Says States Should Be Able To Legalize Marijuana, Even If He Prefers ‘Medical Margaritas’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Searching for Escorts in Connaught Place Hotel New Delhi gave me access to well-organized listings. The profiles were detailed, and communication was quick and clear. It helped in making decisions easily without second thoughts. Services in this location seem to focus on user satisfaction, offering a balanced mix of convenience and proper coordination.

Current federal laws that determine how marijuana and other drugs are classified have “fundamental flaws” that have done “immense damage,” according to a new analysis coauthored by a former Drug Enforcement Administration (DEA) senior advisor. While the Department of Justice and its component agency DEA are currently working to finalize a rule to move cannabis from Schedule I of the Controlled Substances Act (CSA) to Schedule III in accordance with an executive order from President Donald Trump, the agency’s “choices about how to regulate marijuana are sharply—and irrationally—constrained” by existing law, Matthew Lawrence, the former DEA official, argued in the new paper that he coauthored with Columbia Law School’s David Pozen. “These schedules often force regulators into a Hobson’s choice between overcriminalizing drugs, through prohibitions that predictably backfire, or overcommercializing drugs, through hands-off approaches that leave users vulnerable to corporate exploitation,” Pozen and Lawrence, who worked in the office of the DEA deputy administrator from 2022 to 2023 and who is now at Emory University School of Law, write. Rather than relying on criminal prohibition, the U.S. should instead look to what the authors call “capitalism controls” to more effectively regulate drugs, they say. “US drug policy relies far too much on criminal prohibitions and far too little on what might be called capitalism controls. Criminal prohibitions have been shown time and again to be ineffective for widely used, habit-forming products. Worse than ineffective, they can lead illegal sellers to develop more-potent variants of, or substitutes for, whichever drug is the latest law enforcement priority. And yet, these prohibitions are a central pillar of the CSA and its state-level counterparts, with enormous costs in terms of arrests, imprisonments, and the undermining of racial justice and civil liberties.” Capitalism controls, in contrast, focus on things like commercial and public availability, advertising restrictions and pricing policies such as excise taxes. They also involve checks on industry lobbying and restrictions on product additive to make products more addictive. “None of these capitalism controls are present in the CSA,” Lawrence and Pozen say in the paper, which was published in the journal Science. If you’re tired of incremental marijuana rescheduling announcements and interested in the root problem with drug scheduling, or how to fix it, check out my new piece with Dave Pozen, just out in Science! SSRN version here: https://t.co/9DCEGQAuVr — Matthew B. Lawrence (@mjblawrence) March 23, 2026 Additionally, current federal law only allows officials to consider medical benefits when making scheduling decisions, but the paper argues that nonmedical benefits such as religious, creative, social or recreational impacts should be considered, as well as policy benefits such as reduced incarceration that can stem from reform. Because these factors are ignored, “no matter how wisely the DEA might implement the statute…the agency cannot reach a sensible outcome for a popular drug such as marijuana,” the authors argue. “The policy that must change to bring rationality to the regulation of marijuana, along with many other controlled substances, is not the schedule in which marijuana is placed but rather the scheduling system itself.” Taking a cue from how the Environmental Protection Agency approaches pollution control decisions, drug scheduling should consider “a wider range of interests and perspectives, with explicit attention given to the experiences of people who use or prescribe the drug in question,” they say. Even worse than limiting perspectives, however, current scheduling policy “creates an information problem by restricting the very research into drugs’ benefits that might support their reclassification”—as researchers have continually pointed out that restrictions involved in working with Schedule I substances make it much more difficult to carry out their scientific investigations. Looking ahead, Congress should create a new “harm reduction schedule” for drugs like heroin and fentanyl as well as an additional “managed market access schedule” where substances like cannabis and psilocybin could be classified, the paper argues. “Under this latter schedule, marijuana sellers could be subject to a range of capitalism controls, including limits on potency, additives, marketing tactics, coordinated lobbying, and more,” Lawrence and Pozen write. “In the best tradition of federalism, Congress can learn from state legalization strategies that have curbed public health risks while surviving constitutional challenges brought by industry actors. To minimize conflict with state regulatory regimes that meet or exceed federal standards, Congress could further instruct that any firms operating within these regimes qualify for the managed market access schedule—and thus for all of the benefits of federal legal status—either indefinitely or for a transitional period.” This new approach could extend beyond the U.S. and also be adopted on the global stage to reshape international drug control treaties and the scheduling system they created, the paper argues. “Scholars broadly agree that marijuana policy in the United States today is neither coherent nor evidence based, even as they disagree on the solution,” Lawrence and Pozen say. “From the opioid crisis to the prison population boom to the ongoing marijuana mess, the prevailing framework for scheduling psychoactive drugs is a root cause of repeated failure.” “To address this failure, the scientific community needs to stop fighting so much over the classification of specific substances and start focusing on the classificatory and regulatory framework itself,” they conclude. “Enlightened and effective drug policies will never be realized unless the schedules are straightened out.” At a recent congressional hearing, Rep. Alexandria Ocasio-Cortez (D-NY) similarly criticized the current U.S. drug scheduling system—making the case that placing substances like marijuana and LSD in the most restrictive category runs counter to evidence showing their medical potential, hinders research and is associated with criminal penalties that haven’t effectively prevented harms from substance misuse. The post US System For Classifying Marijuana And Other Drugs Does ‘Immense Damage,’ Former DEA Senior Official Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I’m going to read this. I’ll be sure to come back. thanks for sharing. and also This article gives the light in which we can observe the reality. this is very nice one and gives indepth information. thanks for this nice article... situs toto

MA marijuana overhaul bill nears passage; ME cannabis lounge proposal defeated; How to handle high-THC marijuana?; MO psychedelics Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The House Small Business Committee heard testimony from a father of a child with a terminal illness about how marijuana rescheduling could “unlock research and healing, especially for rare diseases.” A Massachusetts legislature conference committee approved a bicameral deal on a bill to double the amount of marijuana a person can legally possess and to overhaul the Cannabis Control Commission. The Maine House of Representatives voted to kill a bill that would have allowed marijuana consumption lounges to operate in the state, subject to local approval. The pro-legalization Drug Policy Alliance published a report on how to address the potential risks of high-THC marijuana products without reverting to recriminalization policies favored by prohibitionist groups. West Virginia Gov. Patrick Morrisey (R) vetoed a bill to allocate medical cannabis revenue that has gone unspent over concerns about federal law, but the state treasurer is now releasing the funds to support substance misuse treatment and law enforcement programs. The Missouri House of Representatives passed a bill to support research on the therapeutic potential of psychedelics like psilocybin and ibogaine for military veterans and first responders. / FEDERAL The Centers for Disease Control and Prevention and the White House Office of National Drug Control Policy issued a health advisory about increasing reports detecting medetomidine in the illegal drug supply. / STATES West Virginia Gov. Patrick Morrisey (R) vetoed legislation to support ibogaine research. A former Indiana attorney general authored an op-ed criticizing Gov. Mike Braun’s (R) openness to legalizing medical cannabis. A Virginia senator expressed concerns about legalizing recreational marijuana sales. Maine lawmakers discussed a bill to establish medical cannabis testing and tracking requirements. An Ohio judge issued a temporary restraining order blocking enforcement of new hemp product restrictions. Colorado regulators published guidance about marijuana businesses failing to pay the second annual payment for their two-year licenses or permits. Oklahoma regulators sent guidance about medical cannabis business compliance inspections. Minnesota’s top marijuana regulator discussed the first sixth months of legal recreational sales. California regulators published a list of authorized industrial hemp firms. The Omaha Tribe of Nebraska is seeking a development partner for its medical cannabis business. New York regulators took action against unlicensed cannabis businesses. Washington, D.C. officials shuttered more unlicensed cannabis businesses. The Alaska Marijuana Control Board Laboratory Testing Working Group will meet on Wednesday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Japanese police arrested a record-high number of people for marijuana last year. / SCIENCE & HEALTH A study “did not detect a statistically significant overall association between state nonmedical cannabis legalization and adolescent [cannabis use disorder]-coded inpatient discharges.” A study indicated that “CBD, at non-bactericidal levels, effectively suppresses multiple virulence mechanisms in [Listeria monocytogenes], highlighting its potential as a novel anti-virulence agent for food safety and therapeutic applications.” / BUSINESS Curaleaf violated federal law by refusing to bargain with a union, the National Labor Relations Board ruled. Missouri retailers sold $119.8 million worth of legal marijuana products in February. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Cannabis rescheduling testimony in Congress (Newsletter: April 7, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Awesome article, it was exceptionally helpful! I simply began in this and I'm becoming more acquainted with it better! Cheers, keep doing awesome! akongcuan

I am impressed. I don't think Ive met anyone who knows as much about this subject as you do. You are truly well informed and very intelligent. You wrote something that people could understand and made the subject intriguing for everyone. Really, great blog you have got here. สมัครสมาชิก ufabet

Very efficiently written information. It will be beneficial to anybody who utilizes it, including me. Keep up the good work. For sure i will check out more posts. This site seems to get a good amount of visitors. เข้าสู่ระบบ สมัครUFABET

On our website, you will discover the profiles of all Akshardham Escorts, complete with their descriptions and distinctive features. Our escorts will assist you in alleviating stress and satisfying your desires for adventurous intimacy or alluring foreplay. Book highly-rated escorts in Akshardham through us and experience a range of services.

“The issue isn’t whether the funds should be used, it’s how they’re used and whether we’re doing it in a responsible, sustainable way.” By Henry Culvyhouse, Mountain State Spotlight This story was originally published by Mountain State Spotlight. Get stories like this delivered to your email inbox once a week; sign up for the free newsletter at https://mountainstatespotlight.org/newsletter. In spite of a veto that could have further delayed the spending of $38 million in medical marijuana money collected over the last four years, state Treasurer Larry Pack (R) now says he will release the funds under the original mandate. Last week, Gov. Patrick Morrisey (R) vetoed a bill that would’ve required the release of medical marijuana funds to help the homeless and expedite child abuse and neglect cases in the court system. He said the bill tied up monies for future spending. In his veto letter, Morrisey wrote, “West Virginia must do better to plan for the future, and it can’t totally pre-commit future revenue streams like this if it’s going to have reserves to invest more in roads, water, sewer, site selection, rail, and future tax cuts.” Morrisey said he was willing to negotiate with the Legislature on how to spend the money. “The issue isn’t whether the funds should be used, it’s how they’re used and whether we’re doing it in a responsible, sustainable way,” governor’s office spokesman Lars Dalseide wrote in an email. But the money was already pre-committed in state code. Pack’s office said 100 percent of that money will now go to various offices and programs prescribed by the original law—more than half to the Office of Medical Cannabis and the remainder of the funds split between a grant program for substance abuse treatment and grants for law enforcement. The move ignores the governor’s wishes for future reserves to tackle infrastructure and tax cuts. In October, a Mountain State Spotlight investigation revealed $34 million had accumulated in an account held by the Treasurer’s Office from the state’s medical marijuana program. Pack’s office said the money hadn’t been spent because of legal concerns surrounding the drug. Currently, marijuana is listed as a Schedule I narcotic under federal law, meaning it has no medical use and is illegal. Pack isn’t the first state treasurer to express concern. State Treasurer John Perdue (D) said his office wouldn’t hold the money in 2018, following passage of the Medical Cannabis Act. Riley Moore (R), who beat Perdue in the 2020 race, never released the money, either. Going into the 2026 Legislative Session, Del. Evan Worrell, R-Cabell, said he read a report about the amassed funds and wanted to change it. He successfully ran a bill that would force the state to spend the money on a commission to to help thousands of child abuse and neglect court cases, and homelessness services. Had the governor not vetoed the bill, the money would have been designated to those things for one year. Money for substance abuse research, treatment and the abuse and neglect commission would continue in the following years. The Treasurer’s Office spokeswoman Carrie Smith said due to the complexity of state and federal laws, the office had been working to release the money for months. She said the money has now been released to the Department of Homeland Security and the Department of Health. This article first appeared on Mountain State Spotlight and is republished here under a Creative Commons Attribution-NoDerivatives 4.0 International License. The post West Virginia Treasurer Allocates Medical Marijuana Revenue Despite Governor’s Veto appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Massachusetts lawmakers have negotiated the details of a bill to double the legal marijuana possession limit for adults and revise the regulatory framework for the state’s adult-use cannabis market. A bicameral conference committee has spent months working out provisions of the legislation after the House of Representatives and Senate passed differing versions last year, and the panel approved a compromise approach on Monday. Sen. Adam Gómez (D) and Rep. Daniel M. Donahue (D), who co-chaired the conference committee, said in a joint statement that the agreement “charts a more promising path forward for cannabis regulation in our Commonwealth.” “The legislation includes a new structure that provides clear accountability and enhances the operations of the Cannabis Control Commission (CCC),” the lawmakers, who also serve as co-chairs of the legislature’s Joint Cannabis Policy Committee, said. “The bill creates new opportunities for small businesses to grow, while providing those historically harmed by marijuana laws with temporary, exclusive access to those opportunities. This bill will allow them to realize their capital and pursue innovative models such as employee-owned businesses.” If approved in its final form by both chambers, which Gómez and Donahue said they expect to happen this week, the bill would then head to Gov. Maura Healey (D) for her signature. Gómez said at Monday’s conference committee meeting that the agreement represents “a forward-looking approach to modernize Massachusetts’s cannabis laws at a high level.” “This legislation recognizes that our cannabis industry has matured and that our regulatory framework must involve along with them,” he said. “The bill strengthens oversight and accountability by restructuring the Cannabis Control Commission, streamlining its leadership and clarifying goals and responsibilities so that the agency can operate more efficiently and transparently. We also make important improvements to public accountability by creating a new portal for reporting illegal conduct, requiring updated reporting on public health impacts and tax policy and studying workplace safety standards. The bill ensures that the industry continues to operate in a way that prioritizes safety, transparency and public trust. This legislation also supports economic opportunity and long-term sustainability by modernizing license caps and providing more flexibility in ownership structures. We help businesses—especially small and emerging operators—remain viable in the competitive market and by expanding pathways for participation by social equity businesses, including exclusive opportunities in the medical marijuana space. We reinforce our commitment to fairness and equitable access. We remove outdated and burdensome requirements such as the vertical integration mandate for medical operators that have created barriers to entry into growth. These changes help level the playing field and ensure that our cannabis economy reflects the diversity and the dynamics of the Commonwealth. Additionally, the bill expands safe and legal access to cannabis. It updates purchase and possession limits, it clarifies delivery rules to create consistency across municipalities and also allows for more modern and reasonable advertising practices within regulated environments. Finally, we take the important steps to address emerging issues in the marketplace, such as regulation of hemp-derived products and categories by directing further study and thoughtful policy development.” Among the proposed revisions to the state’s cannabis law is a section that would increase the personal possession limit for marijuana from one to two ounces. Colorado enacted the same reform in 2021 after that state’s cannabis market matured. In addition to the possession increase, which was included in both chambers’ versions, H.4206 would reduce the size and revise the organization of CCC, while also updating limits on marijuana business licensing. Under both chambers’ versions of the bill, CCC would be comprised of three members rather than the current five. The conference committee report adopts provisions from the House measure that would allow the governor to make all appointments, rather than the Senate approach to give one of the appointments to the attorney general. Under current law, the treasurer also plays a role in appointing commission members, but that will no longer be the case if the legislation is enacted. The new legislation requires that one member of CCC to have a background in social justice, while the other two commissioners need to have backgrounds in public health, public safety, social justice, consumer regulations or the production and distribution of cannabis. The bill will also increase the amount of licenses that a single entity can possess from three to six, while additionally raising from 10 percent to 20 percent the threshold of much equity in a business is considered ownership for the purpose of counting toward the cap on licenses. It also directs regulators to create a list of “delinquent” cannabis businesses that have not paid their debts to other operators for more than 60 days and prevents others from doing business with those on the delinquent list until debts are paid off. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The cannabis regulation proposal’s advancement comes as marijuana businesses in the state have filed a lawsuit aiming to block an initiative to roll back the state’s voter-approved legalization law from reaching the November ballot. If passed, the state wouldn’t revert back to blanket prohibition; rather, it would repeal the commercial recreational sales and personal home cultivation components of the law while still allowing adults 21 and older to possess up to an ounce of cannabis for personal use. Possession of more than one ounce but less than two ounces would be effectively decriminalized, with violators subject to a $100 fine. Adults could also continue to gift cannabis between each other without remuneration. Medical marijuana sales would remain legal. The measure is currently before the legislature after supporters turned in an initial batch of signatures last year, and lawmakers have until May 5 to act on the proposal. If they choose not to enact it legislatively, the campaign would need to go through another round of petitioning and get at least 12,429 certified signatures by July 1 to make the November ballot. Proponents faced skeptical questioning from lawmakers at a hearing of the Joint Committee on Initiative Petitions last month, with several raising concerns about the motivations behind the anti-marijuana measure and its implications for consumers and businesses. A recent Bay State Poll from the University of Hampshire’s States of Opinion Project found that a majority of Massachusetts adults oppose the marijuana sales and cultivation repeal initiative. Meanwhile, in November, the legislature’s Joint Cannabis Policy Committee advanced a bill that would require a study into legal barriers facing first responders who wish to use marijuana in compliance with state law. Regulators would also need to look into the efficacy of marijuana in the treatment of anxiety, depression and post-traumatic stress disorder (PTSD). They would additionally examine laws and policies for cannabis use by police officers and first responders in other jurisdictions and “any other topics the commission deems relevant.” The bill was reported out as lawmakers in a different committee approved separate legislation to provide employment protections for people who use marijuana. Another panel advanced a similar cannabis employment protections bill in September. Meanwhile, the head of Massachusetts’s marijuana regulatory agency recently suggested that the measure to effectively recriminalize recreational cannabis sales could imperil tax revenue that’s being used to support substance misuse treatment efforts and other public programs. To that point, Massachusetts recently reached another marijuana milestone, with officials announcing in February that the state has surpassed $9 billion in adult-use cannabis purchases since the market launched in 2018. A report from the Cannabis Control Commission (CCC) found that legalization is achieving one of its primary goals: disrupting illicit cannabis sales as adults transition to the regulated market. It shows that among adults who reported past-year marijuana use, an overwhelming 84 percent said they obtained their cannabis from a licensed source. Massachusetts lawmakers also recently assembled a bicameral conference committee to reach a deal on a bill that would double the legal marijuana possession limit for adults and revise the regulatory framework for the state’s adult-use cannabis market. In December, state regulators also finalized rules for marijuana social consumption lounges. CCC recently launched an online platform aimed at helping people find jobs, workplace training and networking opportunities in the state’s legal cannabis industry. Separately, lawmakers are also advancing legislation to establish pilot programs for the regulated therapeutic use of psychedelics. The post Massachusetts Lawmakers Reach Deal To Double Marijuana Possession Limit And Restructure Cannabis Regulations appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A Maine Republican lawmaker is calling out colleagues for killing his bill that would have allowed marijuana consumption lounges to operate in the state. On Monday, the House of Representatives voted 108-35 to adopt a committee’s recommendation not to pass the bill, LD 1365 from Rep. David Boyer (R). The lawmaker said members of his own party were “about split” on the vote, wheres the “vast majority” of Democrats voted against allowing his cannabis legislation to advance. Only seven Democrats voted against the Veterans and Legal Affairs Committee’s majority report recommending that the bill not pass, while 65 members of the party supported the move to kill the legislation. Among Republicans, 28 members voted against stalling the measure while 41 backed the motion. “Maine lawmakers showed their contempt for voters today by killing the cannabis hospitality lounge bill,” Boyer, who led the fight to pass cannabis legalization at the ballot about 10 years ago when he was a staffer for the Marijuana Policy Project (MPP), told Marijuana Moment. “This was a core provision of the 2016 citizens initiative that Maine voters approved nearly ten years ago to legalize adult-use cannabis and create safe, regulated social consumption spaces,” he said, referring to portions of the legalization ballot measure that were later negotiated out by the legislature’s Marijuana Legalization Implementation Committee. “There is no good reason to prohibit cannabis hospitality lounges when we allow adults to consume alcohol in public,” Boyer said “It’s time uphold the will of the voters and let adults be adults.” Under the bill, municipalities would be able to license cannabis hospitality lounges where adults over the age of 21 could consume marijuana products. Local officials could also set fees on the businesses. After being locally licensed, the facilities would not need additional approval from the Maine Office of Cannabis Policy or other state officials. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, a Maine campaign seeking to significantly roll back the state’s marijuana law failed to submit signatures by a recent deadline to make the November 2026 ballot, meaning the anti-cannabis activists will need to shift their focus to 2027 if they hope to put the issue before voters. If approved, the initiative would end regulated recreational marijuana sales as approved by voters in 2016. Possession of up to 2.5 ounces of cannabis would remain legal, but adults would no longer be able to grow plants for personal use or buy adult-use cannabis from licensed stores. The campaign behind the measure has criticism from reform advocates, industry stakeholders and certain lawmakers over allegedly misleading signature gathering tactics, Photo courtesy of Mike Latimer. The post Maine Lawmakers Reject Bill To Legalize Marijuana Consumption Lounges appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Advocates have long argued that marijuana legalization is a superior alternative to criminalization. But while that sentiment prevails with the public and a growing number of lammakers, a leading drug policy reform group says it’s nonetheless important to recognize and address potential public health impacts of consumer trends in state-regulated markets—including the rise of high-potency THC products. Prohibitionists have been quick to seize upon reports of adverse health incidents associated with products engineered to maximize THC, whether it’s naturally produced delta-9 THC in marijuana, synthetically manufactured delta-8 THC in hemp or any of the numerous other iterations of the intoxicating cannabinoid. But rather than revert to banning such products outright, officials should prioritize targeted regulations to balance public health and consumer choice, the pro-legalization Drug Policy Alliance (DPA) said in a new report titled “High-THC Marijuana: Protecting Public Health In A Changing Market.” “As product potency rises, so do important public health questions about safety, youth access, and consumer transparency,” it says, adding that DPA’s position is that “legalization must be paired with thoughtful, evidence-based regulation that protects health, enhances safety, and reduces harm.” The organization isn’t necessarily arguing that high-THC cannabis products present an imminent public health threat, pointing to the “mixed body of research” on the potential negative health impacts such as the development of cannabis use disorder, anxiety and other mental health conditions. But there is a need to expand research into the issue and inform public policy, particularly as it concerns youth use and access, DPA said. For some patients, higher concentrations of THC can “help manage pain and other medical conditions,” the report said, so regulations should “consider medical exemptions or alternate provisions to accommodate these patients’ needs.” At the same time, one of the group’s recommendations is to ensure that legal markets offer a diversified array of products that includes low-THC options for patients and consumers. Overall, one of DPA’s top recommendations is to create a “unified regulatory framework for all cannabinoids (including hemp-derived products like delta-8 THC) with consistent standards for testing, labeling, age restrictions, and consumer protections.” Other proposals essentially follow the same line of policy thinking that reform advocates have long pushed for as an alternative to criminalizing cannabis. That is, they want to see research (including opportunities for federal studies) expanded, restrictions such as age-gating enforced to mitigate youth access and tax revenue allocations that support mental health treatment and other public health initiatives. There should also be improvements in “consumer education and product transparency with standardized serving sizes, clear THC content labeling, prominent warning labels, retail education materials, and training for dispensary staff,” the report says. Because there may be health impacts associated with high-THC cannabis, policymakers should additionally consider potential alternatives to blanket bans that still aim to steer the market away from becoming oversaturated with such products. That could include setting prices based in part on THC potency, while also requiring low-THC product availability in the regulated market. Although the science and health impacts of high-THC cannabis is still being studied, one thing is undeniable: There has been a steady rise in the marketing and sale of such products as the state legalization movement has expanded and businesses have responded to consumer demand. DPA’s report is meant to respond to that reality, without ceding the issue to anti-legalization interests that have used fears about the use of these highly potent products to promote prohibitionist policies. Cat Packer, DPA’s director of legal regulation, said in a Q&A about the THC potency issue that “no one should be arrested for marijuana and policies cannot return to bringing back harmful and ineffective criminalization tactics.” “Legal regulation must address the ongoing harms of criminalization that impede on someone’s livelihood and basic needs,” she said. “At minimum, clearing records for all past marijuana arrests and convictions. Not having a criminal record removes barriers to economic opportunities and housing access. Ending criminalization also stops law enforcement from targeting certain communities.” The DPA report concludes by reiterating that high-THC marijuana products “pose complex regulatory challenges that demand a balanced, evidence-based response.” “As product potency increases and markets evolve, policy must keep pace. Failing to modernize regulatory frameworks poses threats to public health, particularly for youth and individuals vulnerable to mental and physical health issues and substance use disorders,” it says. “By aligning hemp and marijuana regulations, strengthening research and data collection, improving product transparency, and implementing safeguards for high-THC products, policymakers can reduce preventable harms while preserving access for adult consumers and medical patients,” it continues. “Public education, responsible retail practices, and reinvestment of tax revenue into treatment and prevention are critical to regulation that balances commercial interests with public health.” Aligning hemp and marijuana rules has become all the more urgently needed as the federal definition of hemp is set to fundamentally change later this year, with a significantly more restrictive threshold for THC to be considered legal hemp. Industry stakeholders say that policy change, which is set to take effect in November under a broader agriculture law President Donald Trump enacted last year, threatens to effectively eradicate the consumable cannabinoid market. “A strong regulatory framework that is grounded in evidence, health, and consumer protections offers the clearest path forward,” DPA said. “Policymakers should heed these recommendations to mitigate risks, promote informed decision-making, and ensure market innovations do not outpace health protections.” Meanwhile, amid shifting state and federal cannabis policies, the White House has scheduled several meetings with cannabis industry and research stakeholders to discuss a proposed enforcement policy for non-intoxicating CBD products. Also in the background, advocates and stakeholders are also eagerly awaiting the finalization of a rule to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). Trump signed an executive order in December directing the attorney general to expeditiously complete that process—which would help streamline cannabis research while allowing state-licensed businesses to take federal tax deductions—but that remains pending. The post Drug Reform Group Lays Out Options To Address High-THC Marijuana’s Risks Without Returning To Criminalization appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

thank you for creating this safe space for women to share their stories - it's so important that we lift each other up and know we're not alone. i appreciate the work you're doing at cookie clicker 2 to support this community.

“This is a careful bill for people, our veterans and first responders, who have carried extraordinary burdens.” By Rebecca Rivas, Missouri Independent After four years of trying, the Missouri House passed legislation Thursday that would require the state to conduct a study on using psilocybin—also known as “magic mushrooms”—and other alternative therapies to treat depression, substance use or as part end-of-life care. Veterans and first-responders would be able to possess the psychedelic if they’re enrolled in a study, where it would be administered by a facilitator. Despite overwhelming support for the idea in past years, Thursday marks the first time the House has sent the bill on to the Senate, with a vote of 137 to 11. Lawmakers amended the legislation last week to include ibogaine, a powerful psychoactive compound derived from an African shrub that’s used to treat addiction, PTSD and traumatic brain injury. Republican state Rep. Renee Reuter of Imperial gave an emotional account of her husband’s struggles with post-traumatic stress disorder during House debate last week. After serving overseas in the U.S. Army in 1993, her husband’s PTSD has “enticed him to do certain things” that have destroyed their marriage and lives. “When he left in 1993 I told my husband, ‘You do whatever you have to do, but come home,’” Reuter said. “In ‘94 when my husband came home, he didn’t come all the way home.” Her son has also been deployed three times overseas and experiences PTSD as well. “Let’s do this for those men and women,” she said. “Let’s give them whatever it is that we need to give them to help them and their families continue to live and be productive members of society.” While the bill was originally focused on helping veterans, Republican state Rep. Matthew Overcast pushed to expand the bill to also include first responders. In 2020, Overcast worked for a company that handled staffing for nurses in New York hospitals, and he saw how the pandemic impacted the hospital workers. “I can tell you from walking through some of those nursing wards,” said Overcast, who is also a veteran. “There was more death that they saw in those few months when it first hit, than even some of our own soldiers have seen in a war.” This bill requires the Missouri Department of Mental Health to provide grants totaling $2 million for the research on alternative therapies, subject to lawmakers approving the appropriation. The state would collaborate on the study with a Missouri university hospital or medical center operated by the U.S. Department of Veterans Affairs in Missouri. The focus of the treatment is on veterans suffering from post-traumatic stress disorder, depression, substance use disorders, or for those who require end-of-life care. The suicide rate among veterans in Missouri is nearly double the state rate and one of the highest in the country. “This is a careful bill for people, our veterans and first responders, who have carried extraordinary burdens that most of us could only be we can’t really even imagine,” Overcast said, “and they endured significant trauma, not only in service to our communities, but to our country as well. It is measured, it is compassionate and it is accountable.” The bill’s sponsor, Republican state Rep. Richard West of Wentzville, said as a former police officer, he was skeptical of alternative therapies at first. But he’s read the study results and believes states should support furthering the research. That includes studies done by psychiatry researchers at Washington University School of Medicine in St. Louis, who were the first in Missouri to give a legal dose of psilocybin in 2019. They have been using a brain-imaging technique to learn how psilocybin affects certain networks in the brain. Republican State Rep. Dave Griffith of Jefferson City, a veteran who has supported the measure for several years, said it was appropriate to add first responders as eligible participants. “I think the most important thing about this bill is going to be done under a controlled atmosphere,” Griffith said, before the House passed the bill Thursday. “There needs to be safeguards put in place for them. [West] set up all those guardrails for us, so I’d ask somebody to support this bill.” This story was first published by Missouri Independent. The post Missouri Lawmakers Pass Bill Supporting Psychedelics Research To Aid Military Veterans And First Responders appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Congressional lawmakers were recently presented with a unique argument in favor of expanding therapeutic access to cannabis and rescheduling marijuana under federal law: Doing so could mitigate threats associated with Chinese Community Party (CCP) operatives. At a hearing before the House Small Business Committee last month, members took expert testimony on a variety of challenges linked to CCP, including intellectual property theft, foreign investments and vulnerabilities in the supply chain that impact small U.S. companies. The hearing—titled “Defending Main Street: Combating CCP Threats to America’s Small Businesses” Summary”—involved testimony from Sean Murphy, founder of the nonprofit organization Kompassion that focuses on palliative care and rare diseases afflicting children. Murphy said his personal experience raising a child with a severe health condition as well as volunteering in veterans hospices informed his advocacy for cannabinoid research and reform. That includes a proposal to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA) to “unlock research and healing, especially for rare diseases,” he said. Rescheduling wouldn’t federally legalize cannabis, but it would remove certain Schedule I research barriers, while benefitting state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an Internal Revenue Service (IRS) code known as 280E. The incremental change “will be a monumental movement in research and development of cures,” Murphy said in a written testimony submitted to the committee. And while marijuana remains Schedule I, President Donald Trump signed an executive order in December directing the attorney general to quickly finalize its reclassification under a process that was initiated under the Biden administration. As part of his testimony for the committee hearing, Murphy also included policy recommendations that he argued would help address lawmakers’ concerns by empowering U.S. entrepreneurs and small business owners in healthcare, while generally expanding their access to capital. One of the recommendations involves targeted funding for energetic medicine, palliative care and cannabinoid research through the Advanced Research Projects Agency for Health (ARPA-H) under the U.S. Department of Health and Human Services (HHS). With funding for ARPA-H currently at $1.5 billion for the 2026 fiscal year, a portion should be side aside to “explicitly” support initiatives such as cannabinoid research, “including new therapeutic pathways made possible by marijuana’s rescheduling from Schedule I to Schedule III,” the testimony says. “All mammals possess an endocannabinoid system (ESC) that plays a central role in inflammation reduction and homeostasis; targeted research in this area would unlock breakthrough whole-health approaches that treat the body’s nervous and endocannabinoid system, while supporting veteran and family care, all while keeping IP and data 100 percent secure from foreign exploitation,” it says. Cannabis policy also intersected with a congressional hearing focused on foreign threats last year, when a GOP-led House committee looked at challenges associated with Chinese criminal organizations behind large-scale illicit marijuana grows. Leveraging the increasing attention to the issue, the prohibitionist group Smart Approaches to Marijuana (SAM) put out an ad in July arguing that if President Donald Trump moved forward with a pending cannabis rescheduling proposal, it would empower Chinese cartels. In 2023, a major marijuana lobbying firm apologized after sending a letter to Senate committee leadership concerning a bipartisan cannabis banking bill that contained “inappropriate” references to investments from China in a “misguided attempt” to push for amendments expanding the legislation. The post Marijuana Rescheduling Could ‘Unlock Research’ To Treat Rare Diseases, Father Of Terminally Ill Child Tells Congressional Committee appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

FBI memo on marijuana investments; Another Medicare hemp coverage rule; NC governor pushes legalization; HI cannabis resolutions Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… BREAKING: Journalism is often consumed for free, but costs money to produce! While this newsletter is proudly sent without cost to you, our ability to send it each day depends on the financial support of readers who can afford to give it. So if you’ve got a few dollars to spare each month and believe in the work we do, please consider joining us on Patreon today. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW President Donald Trump is proposing that Congress continue a rider protecting state medical cannabis laws from federal interference for the first time after suggesting its deletion in prior budget requests—but he is also asking lawmakers to keep blocking Washington, D.C. from legalizing recreational marijuana sales The Federal Bureau of Investigation declassified a guidance memo blocking agents from investing in or working at marijuana companies but allowing involvement with hemp and CBD businesses—except if their packaging depicts a cannabis leaf, which is considered “promotion of marijuana.” The Centers for Medicare & Medicaid Services filed a Federal Register notice finalizing a rule to allow coverage of some hemp products like hulled seed, seed protein powder and seed oil as specialized benefits through Medicare Advantage plans. North Carolina Gov. Josh Stein (D) is stepping up the push to legalize marijuana after the Advisory Council on Cannabis he appointed issued an interim report recommending the state move away from a criminalization-based approach and toward a system of “robust” regulations providing legal access to THC products. The Louisiana Senate Health and Welfare Committee approved a bill to allow patients with terminal and irreversible conditions to use medical marijuana in hospitals, subject to certain limitations. The Hawaii Senate Judiciary Committee approved resolutions calling on Congress to federally legalize marijuana, support state efforts to clear people’s conviction records and take steps to facilitate access to banking services for companies in the cannabis industry. Missouri lawmakers sent Gov. Mike Kehoe (R) a bill to ban intoxicating hemp products, protect marijuana consumers’ privacy and recognize cannabis industry workers’ right to unionize. / FEDERAL Rep. Jim Baird (R-IN) expressed his concerns about the pending federal recriminalization of hemp products at a House Appropriations Subcommittee Agriculture, Rural Development, Food and Drug Administration and Related Agencies hearing. / STATES Former New Jersey Gov. Chris Christie (R) discussed his opposition to legalizing marijuana. Delaware regulators filed proposed changes to marijuana product rules. Missouri regulators filed proposed rules to establish marijuana research facilities. Minnesota regulators published guidance about on-site cannabis consumption. New York’s new top marijuana regulator discussed his plans for overseeing the legal industry. Massachusetts regulators are investigating a whistleblower complaint against a marijuana business. New York cannabis regulators posted an updated form for reporting incidents or complaints. The Illinois Medical Cannabis Advisory Board will meet on Monday. The Georgia Access to Medical Cannabis Commission will meet on Wednesday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL Los Angeles, California regulators sent an update about various cannabis issues. / INTERNATIONAL Saint Kitts and Nevis Prime Minister Terrance Drew spoke about efforts to implement cannabis reform in a “careful and measured” way. Nepal local governments are taking steps to allow cannabis cultivation. / SCIENCE & HEALTH A study found that “Christian participants reported the most favorable views toward both medical and recreational cannabis, followed by Jewish respondents, while Muslim and Druze participants expressed more conservative attitudes.” A study found that “individuals purchased and consumed cannabis regardless of legal status and legal status was not significantly associated with harm or benefit rating, controlling for demographic and use data” and that “individuals appear more likely to purchase through legal means, if available.” / BUSINESS Curaleaf Holdings, Inc.’s chief legal officer extended an existing automatic securities disposition plan. Village Farms International, Inc.’s chief financial officer is leaving the post while remaining an employee of the company. / CULTURE Scarlett Johansson talked about seeing Cypress Hill smoke a very large blunt at the first concert she ever attended. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Trump puts medical cannabis protections in budget (Newsletter: April 6, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Interesting perspective on postpartum depression. While I appreciate the author's candidness, it's crucial to consult healthcare professionals. Individual experiences vary drastically. Perhaps incorporating discussion of professional therapy alongside alternative treatments, and risks, would offer a more balanced view. It reminds me of the focus and calm some find when playing Drift Boss – a temporary escape doesn't replace comprehensive care.

Wow, that's a powerful story! It's disheartening to hear about the lack of support and the reliance on potentially harmful medications like Oxycontin for postpartum depression. It's interesting to consider alternative approaches. It sounds like Samantha found something that worked for her, and it's great she's sharing her experience. It reminds me of simpler times, relaxing and just managing something simple, maybe like playing Papa's Freezeria. Every mom deserves access to options that truly help them, with open discussion and less stigma. Thanks for sharing!

A Louisiana Senate panel has advanced a bill to allow patients with terminal and irreversible conditions to use medical marijuana in hospitals. The Senate Health and Welfare Committee approved the legislation, SB 270 from Sen. Katrina Jackson-Andrews (D), with amendments, in a voice vote on Wednesday. “This bill was brought at the request of constituents who believe that therapeutic medical marijuana, which is already legal in this state, should be offered in hospitals when patients are terminally ill or otherwise in need the comfort of this medicine,” Jackson-Andrews said ahead of the vote. Under the proposal, hospitals would have to create written guidelines allowing covered patients to consume medical cannabis on-site in forms other than smoking or vaping. Under an amendment adopted by the panel, emergency or outpatient departments would be exempted from the policy. The revised legislation also clarifies that patients and primary caregivers are responsible for acquiring and administering medical marijuana, which must be “stored securely at all times in a locked container provided by the patient.” Health care professionals and staff would be prohibited from “administering, storing, retrieving, or assisting the patient with the medical marijuana,” the text says. The amendment, which the sponsor worked on with help from the Louisiana Hospital Association, also allows hospitals to opt out of the policy if federal officials take action against any healthcare facility in the state over medical cannabis use, rather than only allowing those that were specifically targeted to stop complying. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Louisiana, the Senate Health and Welfare Committee last week approved a bill to create a psychedelic-assisted therapy pilot program, using opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin and ibogaine. Lawmakers are also considering a bill to create an adult-use marijuana legalization pilot program in the state to determine whether the reform should eventually be expanded and permanently codified. The post Louisiana Senators Approve Bill To Allow Medical Marijuana Use In Hospitals For Terminally Ill Patients appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

You there, this is really good post here. Thanks for taking the time to post such valuable information. Quality content is what always gets the visitors coming. live casino online

Your work is truly appreciated round the clock and the globe. It is incredibly a comprehensive and helpful blog. live casino

i love reading this article so beautiful!!great job! bolahit daftar